Von Willebrand disease screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:


==Overview==
==Overview==
There is no established screening modality of Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process. Von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.<ref name="pmid23551532">{{cite journal |vauthors=Verfaillie CJ, De Witte E, Devreese KM |title=Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease |journal=Int J Lab Hematol |volume=35 |issue=5 |pages=555–65 |year=2013 |pmid=23551532 |doi=10.1111/ijlh.12087 |url=}}</ref> The use of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia is not sufficiently sensitive to detect Von Willebrand Ristocetin cofactor activity (RCoF) values <50 IU/dl with normal multimer patterns.<ref name="pmid23335259">{{cite journal |vauthors=Naik S, Teruya J, Dietrich JE, Jariwala P, Soundar E, Venkateswaran L |title=Utility of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia |journal=Pediatr Blood Cancer |volume=60 |issue=7 |pages=1184–7 |year=2013 |pmid=23335259 |doi=10.1002/pbc.24456 |url=}}</ref>
There is no established screening modality for Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process. Von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.<ref name="pmid23551532">{{cite journal |vauthors=Verfaillie CJ, De Witte E, Devreese KM |title=Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease |journal=Int J Lab Hematol |volume=35 |issue=5 |pages=555–65 |year=2013 |pmid=23551532 |doi=10.1111/ijlh.12087 |url=}}</ref> The use of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia is not sufficiently sensitive to detect Von Willebrand Ristocetin cofactor activity (RCoF) values <50 IU/dl with normal multimer patterns.<ref name="pmid23335259">{{cite journal |vauthors=Naik S, Teruya J, Dietrich JE, Jariwala P, Soundar E, Venkateswaran L |title=Utility of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia |journal=Pediatr Blood Cancer |volume=60 |issue=7 |pages=1184–7 |year=2013 |pmid=23335259 |doi=10.1002/pbc.24456 |url=}}</ref>


==Screening==
==Screening==
*There is no established screening modality of Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process.
*There is no established screening modality for Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process.
*The von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.<ref name="pmid23551532">{{cite journal |vauthors=Verfaillie CJ, De Witte E, Devreese KM |title=Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease |journal=Int J Lab Hematol |volume=35 |issue=5 |pages=555–65 |year=2013 |pmid=23551532 |doi=10.1111/ijlh.12087 |url=}}</ref>
*The von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.<ref name="pmid23551532">{{cite journal |vauthors=Verfaillie CJ, De Witte E, Devreese KM |title=Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease |journal=Int J Lab Hematol |volume=35 |issue=5 |pages=555–65 |year=2013 |pmid=23551532 |doi=10.1111/ijlh.12087 |url=}}</ref>



Revision as of 18:45, 15 December 2016

Von Willebrand disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Von Willebrand disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Von Willebrand disease screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Von Willebrand disease screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Von Willebrand disease screening

on Von Willebrand disease screening

Von Willebrand disease screening in the news

Blogs on Von Willebrand disease screening

Directions to Hospitals Treating Von Willebrand disease

Risk calculators and risk factors for Von Willebrand disease screening

Von Willebrand disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Von Willebrand disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Von Willebrand disease screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Von Willebrand disease screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Von Willebrand disease screening

on Von Willebrand disease screening

Von Willebrand disease screening in the news

Blogs on Von Willebrand disease screening

Directions to Hospitals Treating Von Willebrand disease

Risk calculators and risk factors for Von Willebrand disease screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

There is no established screening modality for Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process. Von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.[1] The use of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia is not sufficiently sensitive to detect Von Willebrand Ristocetin cofactor activity (RCoF) values <50 IU/dl with normal multimer patterns.[2]

Screening

  • There is no established screening modality for Von Willebrand disease. However, several questionnaires and laboratory investigations have been developed to help in the screening process.
  • The von Willebrand factor antigen and activity have been tried in the screening for von Willebrand disease.[1]
  • The use of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia is not sufficiently sensitive to detect Von Willebrand Ristocetin cofactor activity (RCoF) values <50 IU/dl with normal multimer patterns.[2]
  • Scoring key for the Pediatric Bleeding Questionnaire used in screening Von willebrand disease is shown below:[3]
  • A score of 3 or more is highly predictive of vWD.[3]
Symptom/score -1 0 1 2 3 4
Epistaxis - No or trivial (≤5 per

year)

>5 per year OR >10

minutes duration

Consultation only Packing, cauterization or

antifibrinolytics

Blood transfusion, replacement

therapy or desmopressin

Cutaneous - No or trivial (≤1cm) >1cm AND no trauma Consultation only - -
Minor wounds - No or trivial (≤5 per

year)

>5 per year OR >5

minutes duration

Consultation only or Steristrips Surgical hemostasis or

antifibrinolytics

Blood transfusion, replacement

therapy or desmopressin

Oral cavity - No Reported at least once Consultation only Surgical hemostasis or

antifibrinolytics

Blood transfusion, replacement

therapy or desmopressin

Gastrointestinal

tract

- No Identified cause Consultation or spontaneous Surgical hemostasis,

antifibrinolytics, blood

transfusion, replacement therapy

or desmopressin

-
Tooth extraction No bleeding in at least

2 extractions

None done or no

bleeding in 1

extraction

Reported, no

consultation

Consultation only Resuturing, repacking or

antifibrinolytic

Blood transfusion, replacement

therapy or desmopressin

Surgery No bleeding in at least

2 surgeries

None done or no

bleeding in 1

Reported, no

consultation

Consultation only Surgical hemostasis or

antifibrinolytics

Blood transfusion, replacement

therapy or desmopressin

Menorrhagia - No Reported or consultation

only

Antifibrinolytics or

contraceptive pill use

D&C or iron therapy Blood transfusion, replacement

therapy or desmopressin

Post-partum No bleeding in at least

2 deliveries

No deliveries or no

bleeding in 1 delivery

Reported or consultation

only

D&C, iron therapy or

antifibrinolytics

Blood transfusion, replacement

therapy or desmopressin

-
Muscle hematoma - Never Post-trauma, no therapy Spontaneous, no therapy Spontaneous or traumatic,

requiring replacement therapy or

desmopressin

Spontaneous or traumatic,

requiring surgical intervention

or blood transfusion

Hemarthrosis - Never Post-trauma, no therapy Spontaneous, no therapy Spontaneous or traumatic,

requiring replacement therapy or

desmopressin

Spontaneous or traumatic,

requiring surgical intervention

or blood transfusion

Central nervous

system

- Never - - Subdural, any intervention Intracerebral, any intervention
Other

(eg. umbilical stump bleeding,

cephalhematoma,

post-circumcision bleeding, post-venipuncture bleeding,

and macroscopic hematuria)

- No Reported Consultation only Surgical hemostasis,

antifibrinolytics or iron therapy

Blood transfusion, replacement

therapy or desmopressin

References

  1. 1.0 1.1 Verfaillie CJ, De Witte E, Devreese KM (2013). "Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease". Int J Lab Hematol. 35 (5): 555–65. doi:10.1111/ijlh.12087. PMID 23551532.
  2. 2.0 2.1 Naik S, Teruya J, Dietrich JE, Jariwala P, Soundar E, Venkateswaran L (2013). "Utility of platelet function analyzer as a screening tool for the diagnosis of von Willebrand disease in adolescents with menorrhagia". Pediatr Blood Cancer. 60 (7): 1184–7. doi:10.1002/pbc.24456. PMID 23335259.
  3. 3.0 3.1 Mittal N, Naridze R, James P, Shott S, Valentino LA (2015). "Utility of a Paediatric Bleeding Questionnaire as a screening tool for von Willebrand disease in apparently healthy children". Haemophilia. 21 (6): 806–11. doi:10.1111/hae.12689. PMC 4673659. PMID 25982122.

Template:WH Template:WS